Apellis Pharmaceuticals, Inc. APLS NASDAQ

Apellis Pharmaceuticals, Inc. (APLS) has shown exceptional revenue growth over the past 3 years, expanding from $75M to $1.0B (average +183.8%/yr). Net income reached $22M, reflecting exceptional earnings expansion at +64.3%/yr on average. The net profit margin is 2.2%, which is thin. the company was profitable in 1 out of the last 4 years tracked. The gross margin is 89.8% (high), with a -2.7pp trend over the period. With a $5B market cap and MOAT composite score of 65/100, the company has a moderate competitive position.

Criteria proven by this page:

• GROWTH (100/100, Pass) — proving strong growth momentum
• PAST (25/100, Fail) — the company has frequently reported losses. Looking at the full 13-year history, the company was profitable in 1 of 13 years — a mixed long-term record
• INCOME (30/100, Partial) — the company is profitable but margin is below 15%
• MOAT (65/100, Partial) — some competitive advantages are present but not dominant

Overall SharesGrow Score: 48/100 with 1/7 criteria passed.